{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:35:53Z","timestamp":1786718153418,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi J Gastroenterol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/sjg.sjg_91_17","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T03:13:38Z","timestamp":1505790818000},"page":"275","source":"Crossref","is-referenced-by-count":35,"title":["Optimized high-dose amoxicillin\u2013proton-pump inhibitor dual therapies fail to achieve high cure rates in China"],"prefix":"10.4103","volume":"23","author":[{"given":"Dian-Chun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1319-3767.215047-1","first-page":"1311","volume-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","author":"Marshall","year":"1984","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.215047-2","first-page":"158","volume-title":"Helicobacter pylori 25 years after (1983\u20132008): Epidemiology, microbiology, pathogenics, diagnostics and treatment","author":"Ramirez","year":"2009","journal-title":"Rev Gastroenterol Peru"},{"key":"key-10.4103\/1319-3767.215047-3","first-page":"9","volume-title":"Helicobacter pylori, 13 years after the original publication","author":"Beltran-Garcial","year":"1997","journal-title":"Rev Latinoam Microbiol"},{"key":"key-10.4103\/1319-3767.215047-4","first-page":"27","volume-title":"Helicobacter pylori infection: From gastric to systemic disease","author":"Gasbarrini","year":"2010","journal-title":"Recenti Prog Med"},{"key":"key-10.4103\/1319-3767.215047-5","first-page":"525","volume-title":"Prevalence of Helicobacter pylori resistance to antibiotics and its influence on the treatment outcome in China: A multicenter clinical study","author":"Cheng","year":"2007","journal-title":"Chinese J Gastroenterol"},{"key":"key-10.4103\/1319-3767.215047-6","first-page":"460","volume-title":"The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China","author":"Gao","year":"2010","journal-title":"Helicobacter"},{"key":"key-10.4103\/1319-3767.215047-7","first-page":"14973","volume-title":"Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/1319-3767.215047-8","first-page":"1","volume-title":"Review: Clinical management of Helicobacter pylori infection in China","author":"Xie","year":"2015","journal-title":"Helicobacter"},{"key":"key-10.4103\/1319-3767.215047-9","doi-asserted-by":"crossref","unstructured":"Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012;36:627-34.","DOI":"10.1111\/apt.12014"},{"key":"key-10.4103\/1319-3767.215047-10","first-page":"227","volume-title":"Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication","author":"Yang","year":"2011","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/1319-3767.215047-11","first-page":"6400","volume-title":"Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype","author":"Sugimoto","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/1319-3767.215047-12","first-page":"1129","volume-title":"Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole","author":"Sahara","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.215047-13","first-page":"290","volume-title":"Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status","author":"Sugimoto","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.215047-14","first-page":"312","volume-title":"Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion","author":"Sugimoto","year":"2014","journal-title":"Helicobacter"},{"key":"key-10.4103\/1319-3767.215047-15","first-page":"984","volume-title":"The treatment of Helicobacter pylori infection in the management of peptic ulcer disease","author":"Walsh","year":"1995","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.215047-16","first-page":"514","volume-title":"Review article: The global emergence of Helicobacter pylori antibiotic resistance","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.215047-17","first-page":"35","volume-title":"Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal","author":"Francesco","year":"2011","journal-title":"World J Gastrointest Pathophysiol"},{"key":"key-10.4103\/1319-3767.215047-18","first-page":"353","volume-title":"Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents","author":"Debets-Ossenkopp","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.4103\/1319-3767.215047-19","first-page":"1327","volume-title":"Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent?","author":"Midolo","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/1319-3767.215047-20","first-page":"5","volume-title":"Is continuous infusion of Mactam antibiotics worthwhile \u2013 Efficacy and pharmacokinetic considerations","author":"Mouton","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/1319-3767.215047-21","first-page":"1715","volume-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","author":"Zhang","year":"2015","journal-title":"Gut"},{"key":"key-10.4103\/1319-3767.215047-22","first-page":"895","volume-title":"High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection","author":"Yang","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.215047-23","first-page":"622","volume-title":"New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China","author":"Ren","year":"2014","journal-title":"J Dig Dis"},{"key":"key-10.4103\/1319-3767.215047-24","first-page":"1353","volume-title":"Kyoto global consensus report on Helicobacter pylori gastritis","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"key-10.4103\/1319-3767.215047-25","first-page":"743","volume-title":"Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy","author":"Shirai","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/1319-3767.215047-26","first-page":"301","volume-title":"Acid, protons and Helicobacter pylori","author":"Sachs","year":"1996","journal-title":"Yale J Biol Med"},{"key":"key-10.4103\/1319-3767.215047-27","first-page":"321","volume-title":"New concepts of resistance in the treatment of Helicobacter pylori infections","author":"Graham","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.215047-28","first-page":"8547686","volume-title":"Multicenter study of antibiotic resistance profile of H.pylori and distribution of cyp2c19 gene polymorphism in rural population of Chongqing, China","author":"Han","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"key-10.4103\/1319-3767.215047-29","first-page":"1715","volume-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","author":"Zhang","year":"2015","journal-title":"Gut"},{"key":"key-10.4103\/1319-3767.215047-30","first-page":"1859","volume-title":"Bactericidal and morphological effects of amoxicillin on Helicobacter pylori","author":"Berry","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/1319-3767.215047-31","first-page":"e8704","volume-title":"Morphological and bactericidal effects of different antibiotics on Helicobacter pylori","author":"Faghri","year":"2014","journal-title":"Jundishapur J Microbiol"},{"key":"key-10.4103\/1319-3767.215047-32","first-page":"45","volume-title":"Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy","author":"Sugimoto","year":"2009","journal-title":"Arch Immunol Ther Ex"},{"key":"key-10.4103\/1319-3767.215047-33","first-page":"802","volume-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant helicobacter pylori infections in a prospective study","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.215047-34","first-page":"5283","volume-title":"Treatment of Helicobacter pylori infection: Current status and future concepts","author":"Yang","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:31:47Z","timestamp":1786714307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.SJG_91_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"alternative-id":["215047"],"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_91_17","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}